Jason J. Luke, MD, FACP, on how data from ESMO 2019 may impact the treatment of melanoma

Jason J. Luke, MD, FACP, on the most compelling data in metastatic melanoma from ESMO 2019Подробнее

Dr. Jason Luke Talks About Advances in how Melanoma is DiagnosedПодробнее

Jason J. Luke, MD, FACP, on the role of CAR-Ts in the treatment of solid tumorsПодробнее

Jason Luke, MD: The Impact of BRAF/MEK Inhibitors in MelanomaПодробнее

Dr. Jason Luke Discusses Nivolumab and Pembrolizumab in MelanomaПодробнее

Dr. Jason Luke on Utilizing the Tumor Microenvironment as a Biomarker for Immunotherapy ResponseПодробнее

Dr. Luke Discusses Combination Approaches on Horizon in MelanomaПодробнее

Dr. Jason Luke on Sequencing Targeted and Immunotherapy Agents in BRAF+ MelanomaПодробнее

Dr. Jason Luke Describes Results from the Phase III COMBI-d TrialПодробнее

How Immunotherapy is Administered - Part 1Подробнее

Dr. Luke Discusses the Combination of Epacadostat and Pembrolizumab in MelanomaПодробнее

Dr. Luke on Challenges With Immunotherapy in MelanomaПодробнее

Dr. Luke on the Future Role of Immunotherapy Combinations in MelanomaПодробнее

Dr. Luke on Ongoing Studies With Immunotherapy in MelanomaПодробнее

Jason Luke, MD: Second-Line TherapyПодробнее

Dr. Luke on Treatment Options in Metastatic MelanomaПодробнее

Dr. Luke on Immunotherapy Advancements in MelanomaПодробнее

Immunotherapy in Advanced MelanomaПодробнее

Exploring Intratumoral Immunotherapy in Melanoma and Other MalignanciesПодробнее